Hormonal therapy for acne: why not as first line therapy? facts and controversies

Clinics in Dermatology

Volumn 28, Issue 1, 2010, Pages 17-23

  Katsambas, Andreas D ^a   Dessinioti, Clio ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BUSERELIN; CIMETIDINE; CORTICOSTEROID; CYPROTERONE ACETATE; DEXAMETHASONE; DIANE; DROSPIRENONE; ESTROGEN; ESTROGEN DERIVATIVE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETYNODIOL DIACETATE; FLUTAMIDE; GLUCOCORTICOID; GONADORELIN AGONIST; ISOTRETINOIN; KETOCONAZOLE; LEUPRORELIN; LEVONORGESTREL; NAFARELIN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PREDNISONE; PROGESTERONE DERIVATIVE; SPIRONOLACTONE; UNINDEXED DRUG;

ACNE; AMENORRHEA; ARTICLE; BLOOD CLOTTING DISORDER; BREAST TENDERNESS; CHLOASMA; CLINICAL FEATURE; COMEDO; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENDOMETRIUM ATROPHY; FATIGUE; FLUID RETENTION; GYNECOMASTIA; HEPATITIS; HIRSUTISM; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; HYPERKALEMIA; HYPERTENSION; LEG EDEMA; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MALE TYPE ALOPECIA; MENSTRUAL IRREGULARITY; METRORRHAGIA; NAUSEA; NONHUMAN; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECOMMENDED DRUG DOSE; SEBORRHEA; SIDE EFFECT; SKIN INFLAMMATION; THROMBOEMBOLISM; TREATMENT DURATION; VOMITING; WEIGHT GAIN;

ACNE VULGARIS; ADRENAL CORTEX HORMONES; ANDROGEN ANTAGONISTS; CIMETIDINE; CONTRACEPTIVES, ORAL, HORMONAL; CYPROTERONE ACETATE; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUTAMIDE; GLUCOCORTICOIDS; GONADOTROPIN-RELEASING HORMONE; HIRSUTISM; HUMANS; ISOTRETINOIN; KETOCONAZOLE; MALE; POLYCYSTIC OVARY SYNDROME; SPIRONOLACTONE;

EID: 71849119282     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.03.006     Document Type: Article

References (74)

1. Gollnick H, Cunliffe W, Berson D, et al. Management of acne. J Am Acad Dermatol 2003;49:s2-s5, s20-25.
2. Pochi P.E., and Strauss J.S. Endocrinologic control of the development and activity of the human sebaceous gland. J Invest Dermatol 62 (1974) 191-201
3. Ebling F.J. Hormonal control and methods of measuring sebaceous gland activity. J Invest Dermatol 62 (1974) 161-171
4. Thiboutot D.M., Knaggs H., Galiland K., et al. Activity of type 1 5 alpha reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 136 (1997) 166-171
5. Cunliffe W.J., and Simpson N.B. Disorders of the sebaceous gland. In: Champion R.H., Burton J.L., Burns D.A., et al. (Eds). Textbook of dermatology. 6th ed. (1998), Blackwell Science, Oxford 1927-1984
6. Strauss J.S., Krowchuk D.P., Leyden J.J., et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 56 (2007) 651-663
7. Drucker W.D., Blumberg J.M., Gandy H.M., et al. Biologic activity of dehydroepiandrosterone sulfate in man. J Clin Endocrinol Metab 35 (1972) 48-54
8. Darley C.R., Moore J.W., Besser G.M., et al. Androgen status in women with late onset or persistent acne vulgaris. Clin Exp Dermatol 9 (1984) 28-35
9. Lucky A.W., McGuire J., Rosenfield R.L., et al. Plasma androgens in women with acne vulgaris. J Invest Dermatol 81 (1983) 70-74
10. Mathur R.S., Moody L.O., Landgrebe S., et al. Plasma androgens and sex hormone binding globulin in the evaluation of hirsute females. Fertil Steril 35 (1981) 296-305
11. Schiavone F.E., Rietschel R.L., Sgoutas D., et al. Elevated free testosterone levels in women with acne. Arch Dermatol 119 (1983) 799-802
12. Scholl G.M., Wu C.H., and Leyden J. Androgen excess in women with acne. Obstet Gynecol 64 (1984) 683-688
13. Strauss J.S., Klingman A.M., and Pochi P.E. The effects of androgens and estrogens on human sebaceous glands. J Invest Dermatol 39 (1962) 139
14. Carmina E., and Lobo R.A. Evidence for increased androsterone metabolism in some normoandrogenic women with acne. J Clin Endocrinol Metab 76 (1993) 1111-1114
15. Odlind V., Carlstrom K., Michaelsson C., et al. Plasma androgenic activity in women with acne vulgaris and in healthy girls before, during and after puberty. Clin Endrocrinol 16 (1982) 243-249
16. Vexiau P., Husson C., Chivot M., et al. Androgen excess in women with acne alone compared with women with acne and/or hirsutism. J Invest Dermatol 94 (1990) 279-283
17. Katsambas A., and Papakonstantinou A. Acne: systemic treatment. Clin Dermatol 22 (2004) 412-418
18. Lucky A. Hormonal correlates of acne and hirsutism. Am J Med 98 (1995) 89S-94S
19. Greenwood R., Brummitt L., Burke B., et al. Treatment of acne with either tetracycline, oestrogen/cyproterone acetate or combined therapy: a double-blind laboratory and clinical study. Br Med J 291 (1985) 1231-1235
20. Miller J.A., Wojnarowska F.T., Dowd P.M., et al. Anti-androgen treatment in women with acne: a controlled trial. Br J Dermatol 114 (1986) 705-716
21. Chen W., Thiboutot D., and Zouboulis C.C. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol 119 (2002) 992-1007
22. Thiboutot D., Jabara S., McAllister J.M., et al. Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol 120 (2003) 905-914
23. Katsambas A., and Dessinioti C. New and emerging treatments in dermatology: acne. Dermatol Ther 21 (2008) 86-95
24. Faure M., and Drapier-Faure E. L' acné. Les traitements hormonaux. Ann Dermatol Venereol 130 (2003) 142-147
25. Stewart M.E., Greenwood R., Cunliffe W.J., et al. Effect of cyproterone acetate-ethinyl estradiol treatment on the proportion of linoleic and sebaceic acids in various skin surface lipid classes. Arch Dermatol Res 278 (1996) 481-485
26. Thiboutot D. Endocrinologic evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol 15 suppl 3 (2001) 57-61
27. Van Wayjen R., and van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic, and endocrine effects. Exp Clin Endocrinol Diabetes 103 (1995) 241-251
28. Gollnick H., Albring M., and Brill K. Efficacité de l'acètate de cyprotèrone oral associé à l'ethinylestradiol dans le traitement de l'acné tardive de type facial. Ann Endocrinol 60 (1999) 157-166
29. Mallari R., and Sinclair R.D. Shortness of breath: an uncommon side-effect of cyproterone acetate in the treatment of androgenetic alopecia. Int J Dermatol 41 (2002) 946-947
30. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol 22 (2004) 419-428
31. Akamatsu H., Zouboulis C.C., and Orfanos C.E. Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5-alpha-dihydrotestosterone in vitro. J Invest Dermatol 100 (1993) 660-662
32. Lowenstein E.J. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther 19 (2006) 210-223
33. Krunic A., Giurea A., and Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing dorspirenone. J Am Acad Dermatol 58 (2008) 60-62
34. Leyden J., Shalita A., Hordinsky M., et al. Efficacy of a low-dose oral contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial. J Am Acad Dermatol 47 (2002) 399-409
35. Thorneycroft I. Evolution of progestins. Focus on the novel progestin drospirenone. J Reprod Med 47 suppl 11 (2002) 975-980
36. Thiboutot D. Regulation of human sebaceous glands. J Invest Dermatol 123 (2004) 1-12
37. Lucky A.W., Henderson T.A., Olson W.H., et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 37 (1997) 746-754
38. Redmond G.P., Olson W.H., et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 89 (1997) 615-622
39. Thiboutot D., Archer D.F., Lemay A., et al. A randomized, controlled trial of a low-dose contraceptive 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril 76 (2001) 461-468
40. Koltun W., Lucky A.U., Thiboutot D., et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 77 (2008) 249-256
41. James W.D. Acne. N Engl J Med 352 (2005) 1463-1472
42. Arowojolu A.O., Gallo M.F., Grimes D.A., et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev (2004) CD004425
43. Thorneycroft I.H., Gollnick H., and Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 74 (2004) 123-130
44. Harper J.C. Antiandrogen therapy for skin disease and hair disease. Dermatol Clin 24 (2006) 137-143
45. DeRossi S.S., and Hersh E.V. Antibiotics and oral contraceptives. Dent Clin North Am 46 (2002) 653-654
46. Helms S.E., Bredle D.L., Zajic J., et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 36 (1997) 705-710
47. London B.M., and Lookingbill D.P. Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives. Arch Dermatol 130 (1994) 392-393
48. Degitz K., Placzek M., Arnold B., et al. Congenital adrenal hyperplasia and acne in male patients. Br J Dermatol 148 (2003) 1263-1266
49. Zouboulis C., and Picero-Martin J. Update and future of systemic acne treatment. Dermatology 206 (2003) 37-53
50. Orfanos C.E., Adler Y.D., and Zouboulis C.C. The SAHA sydnrome. Horm Res 54 (2000) 251-258
51. Bunker C.B., Newton J.A., Kilborn J., et al. Most women with acne have polycystic ovaries. Br J Dermatol 121 (1989) 675-680
52. Hart R., Hickey M., and Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18 (2004) 671-683
53. World Health Organization. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. 2nd ed (2003), Geneva, WHO
54. Frangos J., Alavian C.N., and Kimball A.B. Acne and oral contraceptives: update on women's health screening guidelines. J Am Acad Dermatol 58 (2008) 781-786
55. Hamani Y., Sciaki-Tamir Y., Deri-Hasid R., et al. Misconceptions about oral contraception pills among adolescents and physicians. Human Reprod 22 (2007) 3078-3083
56. Tan J.K. Psychosocial impact of acne vulgaris: evaluating the evidence. Skin Ther 9 (2004) 1-3
57. Speroff L., Fritz M.A. Clinical gynecologic endocrinology and infertility, 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 897, 900-2, 912, 916.
58. Kemmeren J.M., Tanis B.C., vandenBosch M.A.A.J., et al. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 33 (2002) 1202-1208
59. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicenter, case-control study. Lancet 348 (1996) 498-505
60. CSM. Cyproterone acetate (Dianette): risk of venous thromboembolism (VTE). Curr Prob Pharmacovigil 28 (2002) 9-10
61. WHO. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 346 (1995) 1582-1588
62. Pini M., Scoditti U., Caliumi F., et al. Risk of venous thromboembolism and stroke associated with oral contraceptives. Role of congenital thrombophilias. Recenti Prog Med 87 (1996) 331-337
63. Parkin L., Skegg D.C., Wilson M., et al. Oral contraceptives and fatal pulmonary embolism. Lancet 355 (2000) 2133-2134
64. Vasilakis-Scaramozza C., and Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 358 (2001) 1427-1429
65. Farmer R.D., Lawrenson R.A., Todd J.C., et al. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General practice research database and the UK Mediplus database. Hum Reprod Update 5 (1999) 688-706
66. Franks S., Layton A., and Glasier A. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Human Reprod 23 (2008) 231-232
67. Vessey M., and Painter R. Oral contraceptives use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 95 (2006) 385-389
68. Moreno V., Bosch F., Munoz N., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC Multicentric Case-control Study. Lancet 359 (2002) 1085-1092
69. Smith J., Green J., de Gonzalez A., et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361 (2003) 1159-1167
70. Royar J., Becher H., and Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 95 (2001) 370-374
71. Ness R.B., Grisso J.A., Klapper J., et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE study group. Steroid Hormones and Reproductions. Am J Epidemiol 152 (2000) 233-241
72. American College of Obstetricians and Gynecologists. Oral contraceptives for adolescents: benefits and safety (1999), ACOG, Washington (DC)
73. Expert Working Group Meeting to update the selected practice recommendations for contraceptive use. Selected practice recommendations for contraceptive use. 2nd ed. (2004), Geneva, World Health Organization
74. World Health Organization and US Agency for international development. Recommendations for updating selected practices in contraceptive use. Vol 1 (1994), World Health Organization and US Agency for International Development, Washington, DC